KKR to acquire Biosynth Carbosynth from Armira and ceo Urs Spitz

Kohlberg Kravis Roberts & Co (KKR), a global investment firm, and Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company, have entered into an agreement where KKR will acquire Biosynth Carbosynth from Armira and ceo Urs Spitz.

Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on its next chapter of growth. Financial details of the transaction, which is subject to customary regulatory approvals, were not disclosed.

The advisors

Bär & Karrer acts as legal advisor to Armira and Urs Spitz in this transaction. The team is co-led by Christoph Neeracher (pictured left) and Raphael Annasohn (pictured right)and further includes Lukas Bründler, Nicola Kummer and Lazar Lepir (all m&a), Susanne Schreiber, Raoul Stocker, Elena Kumashova and Patrick Schmid (all tax), Markus Wang and Annina Läubli (both IP/IT), Rehana Harasgama (data protection), Kilian Müller (real estate), Laura Widmer and Fanny Sutter (both employment), Ralph Malacrida and Tim Salz (both financing) as well as Mani Reinert and Tobias Rebmann (both antitrust).

Homburger acts as Swiss counsel to KKR. The Homburger team is led by partner Dieter Gericke (corporate / m&a, pictured left) and includes partners Gregor Bühler (IP / IT, employment and executive compensation), Reto Heuberger (tax), Richard Stäuber (competition, regulatory), lead associate Marc Hanslin and associates Romain Fakhoury and Jasmin Künzle (all corporate / m&a), Philippe Weber (tax) and Florian Brunner (competition, regulatory).